rabbit - I certainly don't mind a good old-fashioned debate. I...

rabbit - I certainly don't mind a good old-fashioned debate. I know you've been around this stock too for a long time.

It will be quite some time before they lower the price to the level it will take for this to take on blockbuster proportions. If that were not the case, we would not be sitting on .26 at this stage.

The investment community (especially those in AU that follow biotechs) are well aware of the Epitan/Clinuvel story. I don't come across serious biotech investors in AU who are not familiar with the Epitan/ Clinuvel saga. So, in AU, it's not like this mgmt team is under the radar and it's this undiscovered gem.

There is a lot of smart money that has been in and out of this stock over the years. Trust me, smart investors are watching this closely and would not still be sitting on the sidelines with a horde of cash with CUV at .26 if we were to see a life-changing, crescent run anytime soon.

I still say it's a good investment over the long run, but it's no longer a great trading stock (that was Epitan). IMO anyone who thinks there is going to be monster off-label sales with a 4 figure implant is not being realistic. And I don't see them lowering the price as soon as many on these boards think.

Remember, several posters across the street said when we got into Phase III this would be $2 per share. That has not even come close. There has been a lot of delusion with this stock. Many fell in love with the story, but the script has to be rewritten with the new price point, with the difficulty of getting significance in PLE trials, and with the regulators not keen on off-label usage.

Wolgen himself has said this is not for cosmetic usage. And yes, while he is not dumb enough to encourage off-label usage before regulatory approval (or even soon afterwards), I really think you all will be surprised to see post-approval how against off-label usage he will be.

And as for the management team ticking off the boxes, the delays have cost shareholders a lot in terms of opportunity costs.

BTW, they did not convince the FDA to allow them to advance to Phase III and are a couple years behind on branding the drug. Sorry, but I'm going to be more objective about this despite still holding a considerable amount.

I am not saying that at this price, at this stage of the game, this is not a good investment. I think it is, but it is not a great trade for those who are agressive traders.

just my opinions...GLTA